Trial Profile
A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Antiplatelets
- Indications Coronary artery disease; Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms EPIC-CAD
- 22 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 22 Dec 2023 Planned primary completion date changed from 15 Sep 2023 to 15 Dec 2024.
- 30 Nov 2022 Planned primary completion date changed from 15 Jul 2023 to 15 Sep 2023.